Drugs / R-(-)-Gossypol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00891072 | Jul 2009 → Apr 2011 | Burkitt lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +7 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00540722 | Jan 2008 → Jun 2012 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R-(-)-Gossypol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00891072 ↗ |
| Route | Oral | “Patients receive oral R-(-)-gossypol once daily on days 1-21.” NCT00540722 ↗ |